William Ackman
Bill Ackman runs hedge fund Pershing Square Capital, which he started in 2003 following the dissolution of Gotham Partners.
Ackman is a value investor with an activist bent. Activist investors agitate management for changes. He owns large positions in Target (NYSE: TGT) and Borders (NYSE: BGP). He has also been involved in activist situations at Wendy's (NYSE: WEN) and McDonald's (NYSE: MCD).
Ackman proved his acumen as a short seller in 2007/2008 as short positions he held in MBIA (NYSE: MBI) and Ambac (NYSE: ABK) proved to be big winners due to the credit crunch.
In July 2008, Ackman said he was short the common stock of Fannie Mae (NYSE: FNM) and Freddie Mac (NYSE: FRE). Ackman also laid out a plan to reorganize the GSEs, which would wipe out the common shareholders.
View Older Stories View More Recent Stories
-
Exclusive: Fidelity star Danoff grows cautious about unicorn phenomenon
-
Herbalife, CEO prevail in 'pyramid scheme' lawsuit
-
Pre-Open Stock Movers 11/24: (SUNE) (TASR) (BDBD) Higher; (UNXL) (CHS) (KBIO) Lower (more...)
-
After-Hours Movers 11/23: (XRX) (DY) (VRX) Higher; (BRCD) (CERE) (YY) Lower (more...)
-
Bill Ackman 'has killed Pershing Square. Its over'- Hempton (VRX)
-
Ackman boosts stake in drugmaker Valeant
-
Market Wrap: Pfizer, Allergan Make it Offiical; Icahn Gets Active on Xerox; Existing Sales Slump in Oct.
-
Ackman's Pershing Square Capital Raises Stake in Valeant Pharmaceuticals (VRX) to 9.9%
-
Ackman's Pershing Square Moves Stake in Valeant Pharma (VRX) to 9.9%
-
Hedge funds' favorite stocks lag broader market: Goldman data
-
Ackman's Pershing Square Holdings off 24.5 percent YTD
-
Pershing Square Scholarship winners announced for the Oxford 1+1 MBA
-
Norfolk Southern hostile to Canadian Pacific's $28.4 billion bid
-
Ackman discusses long Valeant Pharma (VRX), short Herbalife (HLF) at Robin Hood
-
Soros Fund Management exits its bet on Herbalife
-
Prominent funds piled into Valeant ahead of tailspin
-
Ackman's Pershing Square 13F Shows 43.37M Stake in Mondelez (MDLZ), Maintained Air Products (APD), Canadian Pacific (CP), Valeant (VRX)
-
Ackman's Pershing Square Down 2.8% MTD, 21.2% YTD
-
Valeant, Ackman must face U.S. insider trading lawsuit
-
Market Wrap: OECD Warns on Trade Growth; Citron Selects New Target; DuPont Names New Chief
-
Ackman says Valeant stock 'extraordinary bargain'
-
Bill Ackman sees Valeant Pharma (VRX) de-levering dramatically over the next 18-24 months - Bloomberg
-
Bill Ackman said Valeant Pharma (VRX) is its largest position
-
Ackman Discuses Valeant Pharma (VRX) on Today's Call
-
Bill Ackman says Zoetis (ZTS) extremely diversified
-
Bill Ackman said Canadian Pacific Railway (CP) managed well through recent headwinds - Bloomberg
-
Bill Ackman said Air Products (APD) can deliver EPS growth with cost controls
-
Bill Ackman sees vast margin expansion at Mondelez (MDLZ)
-
Ackman says Valeant likely to pay down debt in the next 18 months
-
Valeant investors divided on fate of CEO Pearson
-
Big bets on Valeant hit some hedge funds hard in October
-
Goldman sold 1.3 million Valeant shares backing loan to CEO, Valeant says
-
Pershing Square Holdings, Ltd. Releases Communication From Bill Ackman to Valeant Pharmaceuticals International CEO Mike Pearson
-
Is a 'Fire Sale' in Store for Valeant Pharma (VRX)?
-
Ackman, in email, says supports Valeant CEO Pearson
-
Bill Ackman supports Valeant Pharma (VRX) CEO Pearson - CNBC
-
FIRST ® Honors Michael Bloomberg, will.i.am, and Diana Lee Guzman for Advancing STEM Education in Underserved Communities During Inaugural FIRST, Inspire Award and Charity Event
-
Herbalife (HLF) Gains on Anti-Ackman Trade
-
Three Reasons Valeant (VRX) is Plunging Today
-
Ackman backs Valeant CEO as shares tumble to 2-1/2 year lows
-
Valeant (VRX) In Free Fall as Large Holders May Finally Be Crying Uncle
-
Ackman Stocks Trade Lower on Valeant (VRX) Free-Fall
-
Icahn Speculation Around Valeant (VRX) Grows Following Interview
-
Hedge fund Marcato gains 8.4 percent in October: source
-
Valeant's crisis fuels feud between Ackman and Australian fund manager Hempton
-
Ackman's fund lost 7.3 percent in October, off 19 percent for year
-
Bill Ackman's Pershing Square Down 19% YTD (VRX)
-
Goldman Sachs says Valeant has long road ahead, cuts rating
-
Citron's Left said "I have nothing with Bill Ackman. This is about Valeant (VRX)"
-
Citron publishes no new allegations against Valeant, shares rise

